JSI-1187

DRUG2 trials

Sponsors

JS InnoPharm, LLC

Conditions

MelanomaNSCLCSolid TumorSolid Tumors

Phase 1

JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK Pathway Mutations

SuspendedNCT04418167

JS InnoPharm, LLCSolid Tumors

Start: 2020-06-18End: 2025-12-31Updated: 2025-09-03

ERK Inhibitor JSI-1187 in Advanced Solid Tumors

RecruitingNCT06239623

JS InnoPharm, LLCMelanoma, NSCLC, Solid Tumor

Start: 2022-04-02End: 2024-12-30Target: 60Updated: 2024-02-02

Related Papers

Phase 1 study of ERK inhibitor JSI-1187 for patients with advanced solid tumors with MAPK pathway mutations.

Journal of Clinical Oncology2024-06-011 citations